A Phase 1b/Pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's sarcoma: AIDS malignancy consortium trial 059 Journal Article
| Authors: | Ignacio, R. A. B.; Lee, J. Y.; Rudek, M. A.; Dittmer, D. P.; Ambinder, R. F.; Krown, S. E.; for the AIDS Malignancy Consortium (AMC)-059 Study Team |
| Article Title: | A Phase 1b/Pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's sarcoma: AIDS malignancy consortium trial 059 |
| Abstract: | Vascular endothelial growth factor (VEGF) plays an important role in Kaposi's sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received 3 different doses of PTC299. Adverse events typically observed with VEGF inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KS-associated herpesvirus DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KS-associated herpesvirus proliferation. |
| Keywords: | doxorubicin; hypoxia; malignancy; in-vitro; double-blind; active antiretroviral therapy; pegylated liposomal; vascular endothelial growth factor (vegf); protein-coupled receptor; endothelial-growth-factor; factor messenger-rna; kaposi's sarcoma (ks); vascular endothelial growth factor inhibitor (vegf inhibitor); kaposi's; sarcoma-associated herpesvirus (kshv/hhv-8); hiv/aids-related; pharmacokinetics (pk); internal ribosome entry; herpesvirus-infection |
| Journal Title: | JAIDS: Journal of Acquired Immune Deficiency Syndromes |
| Volume: | 72 |
| Issue: | 1 |
| ISSN: | 1525-4135 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2016-05-01 |
| Start Page: | 52 |
| End Page: | 57 |
| Language: | English |
| ACCESSION: | WOS:000375067600017 |
| PROVIDER: | wos |
| PMCID: | PMC4838493 |
| PUBMED: | 26689971 |
| DOI: | 10.1097/QAI.0000000000000918 |
| Notes: | Article -- Source: Wos |
